Brain Stem Glioma

12 registered clinical trials studyying Brain Stem Glioma — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Effect of Antineoplaston Therapy on the QT/QTc Interval In Subjects With Diffuse, Intrinsic, Brainstem Glioma NCT02864888	Burzynski Research Institute	Phase 3
Not Yet Recruiting	Study of Antineoplaston Therapy + Radiation vs. Radiation Only in Diffuse, Intrinsic, Brainstem Glioma NCT02887040	Burzynski Research Institute	Phase 3
Terminated	Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dos NCT03396575	University of Florida	Phase 1
Terminated	Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Unde NCT01884740	Weill Medical College of Cornell University	Phase 1 / Phase 2
Completed	Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Ponti NCT01514201	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	Convection-Enhanced Delivery of 124I-Omburtamab for Patients With Non-Progressive Diffuse Pontine Gliomas Prev NCT01502917	Y-mAbs Therapeutics	Phase 1
Completed	Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Tem NCT01236560	National Cancer Institute (NCI)	Phase 2 / Phase 3
Completed	Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions NCT01082926	City of Hope Medical Center	Phase 1
Active Not Recruiting	Methionine PET/CT Studies In Patients With Cancer NCT00840047	St. Jude Children's Research Hospital	Phase 2
Terminated	Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma NCT01095094	Case Comprehensive Cancer Center	Phase 2
Completed	Immunotherapy for Patients With Brain Stem Glioma and Glioblastoma NCT00576641	Cedars-Sinai Medical Center	Phase 1
Completed	Safety Study of Tarceva in Children With Refractory and Relapsed Malignant Brain Tumors and Newly Diagnosed Br NCT00418327	Gustave Roussy, Cancer Campus, Grand Paris	Phase 1